Immunoreactive vasopressin in end stage renal failure
N B Argent1, P H Baylis, R Wilkinson
1Department of Medicine, University of Newcastle upon Tyne, UK.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|October 15, 1990
Summary
Patients with end-stage renal failure have elevated plasma arginine vasopressin. This study confirms the elevated levels are not due to assay interference, validating findings in kidney failure research.
Area of Science:
- Nephrology
- Endocrinology
- Physiology
Background:
- Patients with end-stage renal failure (ESRF) exhibit higher plasma arginine vasopressin (AVP) levels compared to healthy individuals.
- The cause of elevated AVP in ESRF has been questioned, with potential interference in radioimmunoassays suggested.
Purpose of the Study:
- To investigate whether elevated plasma AVP concentrations in patients with ESRF are due to non-specific interference in the vasopressin radioimmunoassay.
- To confirm the identity of immunoreactive vasopressin in ESRF plasma.
Main Methods:
- Plasma samples from patients with severe chronic renal failure and healthy controls were analyzed.
- High-performance liquid chromatography (HPLC) was used to separate plasma components.
- Radioimmunoassay (RIA) was employed to quantify vasopressin levels in separated fractions.
Main Results:
- Immunoreactive vasopressin in ESRF plasma coeluted with synthetic vasopressin, indicating identical elution volumes.
- Chromatographic assays of all fractions yielded identical patterns for both renal failure and healthy control groups.
- These findings rule out non-specific depression of binding in the vasopressin RIA by circulating substances in renal failure.
Conclusions:
- The elevated plasma concentrations of arginine vasopressin in end-stage renal failure are genuine and not an artifact of the radioimmunoassay.
- The identity of immunoreactive vasopressin in ESRF plasma is confirmed to be consistent with synthetic vasopressin.
- This study validates the physiological significance of increased vasopressin levels in patients with kidney failure.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
01:29Acute Kidney Injury II: Pathophysiology
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...